Left ventricular hypertrophy (LVH) by standard 12-lead electrocardiography (ECG) or echocardiography is associated with a higher risk for cardiovascular disease (CVD) morbidity and mortality among both the general population and hypertensive patients. [1] [2] [3] [4] The associations are independent of cardiovascular risk factors including age, high blood pressure (BP), diabetes mellitus, and obesity. 5 There are at least 2 important determinants of LVH: hemodynamic factors and nonhemodynamic factors. Hemodynamic factors include high BP. In particular, higher nocturnal BP has been shown to be associated with LVH in hypertensive patients. 6, 7 Nonhemodynamic factors in relation to LVH include higher sympathetic nerve activity (SNA) and abnormal hemostatic parameters. [8] [9] [10] [11] [12] Whether ECG-LVH in hypertensive patients is associated with a higher risk of CVD events, independently of 24-hour BP (including nocturnal BP), SNA, and hemostatic factors has been less examined.
January 1992 and 1 January 1998. At baseline, we excluded 10 patients who had a preexisting stroke, coronary artery disease, chronic heart failure, cardiac arrhythmia (including atrial fibrillation), peripheral vascular disease, or obvious comorbidity (i.e., malignancy or infection). As a result, 811 patients were included in the JMS-ABPM Wave 1 Study, of whom 810 patients were successfully followed up (follow-up rate: 98%).
In the present study, we included 514 patients who underwent an ABPM, ECG, and blood sampling at baseline. The included patients (n = 514) showed no significant differences in age (72.2 vs. 72.4 years), a proportion of men (37% vs. 41%) and current smoker (22% vs. 18%), 24-hour BP (138/78 vs. 138/78 mm Hg), and antihypertensive medication use at follow-up time (57% vs. 46%) compared to those not included in the present study (n = 297). The body mass index (BMI) was higher in the included patients compared to those not included (24.2 vs. 23.5 kg/m 2 , P = 0.01).
Office BP was measured at the right arm with the patient in a sitting position after he or she had rested for at least 5 minutes. Office BP was calculated as the average of 2 measures on 2 separate occasions. Diabetes mellitus was defined as a fasting glucose level ≥ 126 mg/dl, a random nonfasting glucose level ≥ 200 mg/dl, hemoglobin A1c ≥ 6.2%, or the use of antihyperglycemic medication.
The study protocol was approved by the Research Ethics Committee of the Department of Cardiovascular Medicine, Jichi Medical School, Japan, in 1998. All participants signed informed consent forms to participate in this study.
24-hour aBPM
All hypertensive patients performed noninvasive 24-hour ABPM at 30-minute intervals on a weekday. Patients who were prescribed antihypertensive medications (n = 285) stopped them for at least 14 days before performing ABPM. Nocturnal BP was defined as the average BP measured from the time when patients went to bed until the time they got out of bed, and awake BP was defined as the average BP measured over the rest of the day. Nocturnal BP dipping was calculated as 100 × (1 − nocturnal systolic BP (SBP)/awake SBP). 13 We divided the patients into 4 groups according to the extent of nocturnal BP dipping as follows: extreme dippers, for whom the nocturnal SBP fall was ≥20%; dippers, for whom the fall was ≥10% but <20%; nondippers, for whom the fall was ≥0% but <10%; and reverse dippers, for whom the fall was <0%.
Measurement of neurohumoral and hemostatic factors
Blood samples were taken from the cubital vein within 2 months after ABPM was conducted. Patients were instructed to fast overnight before the exam. Blood samples were obtained in the morning (8 am-10 am) after 10 minutes in the supine position by the 2-syringe method into disposable siliconized vacuum glass tubes containing a 1/10 volume of 3.8% trisodium citrate for the measurement of hemostatic factors, and disodium EDTA for assaying neurohumoral factors. Serum epinephrine and norepinephrine levels were measured by high-pressure liquid chromatography (HLC-725CA Reagent Reactant D; Tosoh Co., Ltd., Tokyo, Japan). The plasma fibrinogen level was determined using a 1-stage clotting assay kit (Dade Behring, Fort Lauderdale, FL). The plasma levels of F1+2 and PAI-1 antigen were determined using enzyme-immunosorbent assay kits for F1+2 (Behringwerke AG, Marburg, Germany) and PAI-1 (Biopool, Umea, Sweden). The plasma level of the vWF was measured using a specific ELISA kit (Shield Diagnostics, Ltd., Dundee, United Kingdom). This assay uses a monoclonal antibody against the functional epitope of vWF 17 rather than the polyclonal antibody, and the value for the commercially available pooled plasma (CTS standard plasma; Behringwerke AG) was taken as 100%. All measurements were conducted at a single commercial laboratory (SRL Inc., Tokyo, Japan) and the intra-assay and inter-assay coefficients of all tests were <7%.
Definition of Ecg-LVH
ECG-LVH was defined as a high voltage of the QRS complex (R in V 5 + S in V 1 > 3.5 mV) with either a flat T wave (<10% of the R wave) or ST-segment depression and biphasic T waves. 18 
Follow-up and events
Each patient's medical records were reviewed after the patients were enrolled in the present study, and at that time we ascertained whether the patients were using antihypertensive medication or had had any incident CVD events (i.e., myocardial infarction or stroke). The follow-up assessments were performed over a 20-month period between 1996 and 1998, and the mean period of follow-up was 41 months (1-68 months). [13] [14] [15] [16] When patients failed to come to the clinic, we interviewed them by telephone: none of them were diagnosed as having CVD events. Stroke events were diagnosed by the individual physicians who were caring for the patients at the time of the CVD events, and an independent neurologist reviewed the cases and confirmed the diagnosis of stroke events. Stroke was defined as a sudden onset of neurological deficit that persisted for ≥24 hours in the absence of any other disease process that could explain the symptom. Stroke included ischemic stroke (cerebral infarction and cerebral embolism), hemorrhagic stroke (cerebral hemorrhage and subarachnoid hemorrhage), and undefined type of stroke. Myocardial infarction was diagnosed based on the criteria of the WHO Multinational Monitoring of Trends and Determinants in the Cardiovascular Disease (MONICA) project. 19 Transient ischemic attack and angina were not included as outcomes.
Statistical analysis
All statistical analyses were performed with SPSS version 20.0 software (SPSS, Chicago, IL). Variables with normal distribution were expressed as means ± SD, and variables with skewed distribution were expressed as the median (interquartile range). The demographic variables and clinical characteristics in patients with and without ECG-LVH Data are means ± SD or percentage, and P values were obtained by an unpaired t-test or chi-square test. Variables with skewed distributions (asterik) are expressed as median (interquartile range), and P values were obtained by Mann-Whitney U-test. Significance was defined as P < 0.05. eGFR was calculated by the modification of diet in renal disease study equation modified for Japanese, using the following equation: eGFR (ml/min/1.73 m 2 ) = 194 × age (years) −0.287 × serum creatinine (mg/dl) −1.094 (for women, ×0.739).
Abbreviations: ACE, angiotensin converting enzyme; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVH, left ventricular hypertrophy; PR, pulse rate; SBP, systolic blood pressure.
were compared using unpaired t-test. Categorical parameters were compared using chi-square test. Circulating levels of norepinephrine and hemostatic factors were compared using Mann-Whitney U-test. The cumulative incidence rate of CVD events among those with and without ECG-LVH was plotted as a Kaplan-Meier curve, and the difference was tested by the log-rank test. The hazard ratio (HR) and 95% confidence interval (95% CI) of CVD events for ECG-LVH were calculated using Cox regression analysis, including age, gender, smoking status, presence of diabetes mellitus, and the use of antihypertensive therapy at the time of final follow-up as adjusted factors. These adjusted factors were selected since they were significantly different between the hypertensive patients with and without ECG-LVH. We further included 24-hour or nocturnal SBP, circulating norepinephrine level, and plasma fibrinogen as adjusted factors. We assessed the interactions between ECG-LVH and BP parameters (i.e., high 24-hour BP, extreme dipping, and reverse dipping) or neurohumoral and hemostatic factors in relation to CVD events. A 2-sided P < 0.05 was defined as significant.
rESuLTS
The demographic variables and clinical characteristics according to the presence or absence of ECG-LVH at baseline are shown in Table 1 . Patients with ECG-LVH (n = 106) were older and had a higher prevalence of men, current smoking, and diabetes mellitus compared with those without ECG-LVH. Office SBP and diastolic BP (DBP), 24-hour SBP and DBP, daytime SBP and DBP, and nighttime SBP and DBP were higher in patients with ECG-LVH than those without it (all P < 0.001). Table 2 shows comparisons of the neurohumoral and hemostatic factors between patients with and without ECG-LVH. Patients with ECG-LVH showed higher levels of norepinephrine than those without ECG-LVH (P < 0.001), whereas there were no significant differences in plasma renin activity, and circulating levels of fibrinogen, F1+2, vWF, and PAI-1 between the 2 groups.
During follow-up (average of 41 months, range 1-68 months, 1,751 person-years), 43 stroke (ischemic 30, hemorrhagic 5, undefined 8) and 3 myocardial infarction occurred. The Kaplan-Meier curve (Figure 1 ) shows that those with ECG-LVH had a higher cumulative incidence rate of CVD events compared to those without ECG-LVH (P < 0.001 by log-rank test). The Cox regression analysis showed that the patients with ECG-LVH had a higher risk of CVD events, and the association remained significant after adjustment for age, gender, smoking status, presence of diabetes mellitus, and the use of antihypertensive drugs at the time of follow-up (model 1 in Table 3 Hazard ratios (HRs) and 95% confidence interval (CI) of each BP indices are shown. Each model was adjusted by age, gender, smoking status, presence of diabetes mellitus, and the use of antihypertensive drugs at follow-up time. To assess the interaction between ECG-LVH and BP parameters in relation to CVD events, model 2b included ECG-LVH, high 24-hour BP, and ECG-LVH × high 24-hour BP, model 6b included ECG-LVH, extreme dipping, and ECG-LVH × extreme dipping, and model 6c included ECG-LVH, reverse dipping, and ECG-LVH × reverse dipping in the same models. Significance was defined as P < 0.05.
Abbreviations: BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; SBP, systolic blood pressure.
in Table 3 ), extreme dipping (model 6b), or reverse dipping (model 6c) was not observed. We also analyzed the interaction between ECG-LVH and daytime SBP on CVD risk, and the results were null (HR, 1.15; 95% CI, 0.85-1.55, P = 0.35).
The association between ECG-LVH and CVD events was independent of circulating levels of norepinephrine (model 2a in Table 4 ) and fibrinogen (model 3). Higher norepinephrine levels were associated with a higher risk for CVD events independently of ECG-LVH. The interactions of ECG-LVH with norepinephrine (model 2b in Table 4 ) in relation to CVD events were not significant. When we entered the 4 variables (ECG-LVH, high 24-hour BP, and norepinephrine and fibrinogen levels) together in the same model, the CVD risks of ECG-LVH (HR, 4.43; 95% CI, 2.38-8.25) and high 24-hour BP (HR, 4.39; 95% CI, 1.67-11.50) were significant, but the corresponding values of higher norepinephrine (HR, 1.71; 95% CI, 0.91-3.19) and fibrinogen (HR, 1.00; 95% CI, 0.99-1.00) were not significant.
DiScuSSiOn
The present prospective study with older hypertensive patients (mean age 72.3 years and mean follow-up of 41 months) demonstrate that ECG-LVH was associated with a higher risk for CVD events, independent of higher 24-hour BP, nocturnal SBP, and higher circulating levels of fibrinogen and norepinephrine. Each of high 24-hour BP, higher nocturnal SBP, and higher circulating norepinephrine levels was associated with a higher risk for CVD events, independent of the presence of ECG-LVH. There were no significant interactions of ECG-LVH with high 24-hour BP, higher nocturnal SBP, or higher circulating norepinephrine levels in relation to CVD events.
Desai et al. 20 suggested that among 15,792 participants free from clinical CVD at baseline (mean age 54.7 years; 45% men; median follow-up of 11.2 years), ECG-LVH was associated with a higher risk of incident CVD events (i.e., coronary heart disease/nonfatal myocardial infarction, heart failure, stroke, and CVD death) in men (HR, 1.36; 95% CI, 1.10-1.68) and women (HR, 1.43; 95% CI, 1.17-1.94). Office SBP was used as adjusted factors.
Okin et al. 21 suggested that among 8,854 hypertensive patients (mean age 64 ± 7 years; 46% men; mean follow-up of 4.8 years), an LV strain pattern on ECG was associated with a higher risk for CVD mortality (HR, 1.53; 95% CI, 1.2-2.0), independent of conventional cardiovascular risk factors including office SBP. Jissho et al. 22 demonstrated that among 3,230 Japanese elderly (mean age 73.5 years; 43% men; mean follow-up of 2 years), ECG-LVH was a significant predictor of CVD events (particularly cerebrovascular disease) independent of office SBP. None of these studies adjusted for 24-hour BP. Our findings complement and extend the prior evidence [23] [24] [25] by showing that the association between ECG-LVH and the risk of CVD events was independent of high 24-hour BP and higher nocturnal SBP.
Schlaich et al. 8 suggested that among 26 hypertensive patients (mean age 43 years; 75% men), those with echocardiographic LVH had a higher SNA, assessed by muscle SNA, compared to those without LVH. We found that the hypertensive patients with ECG-LVH had higher circulatory norepinephrine levels compared to those without ECG-LVH. Circulatory catecholamine levels are influenced not only by catecholamine production but also by tissue clearance as well as the process of reuptake of catecholamine to neurons, which could attenuate the implications of circulating catecholamine levels as a marker of SNA. 26, 27 Our data suggest that the CVD risk of ECG-LVH was independent of circulating catecholamine levels, but further researches using more precise assessment of SNA are warranted.
Lip et al. 10 suggested that among 178 hypertensive patients (86 men, mean age 54 ± 15 years), those with echocardiographic LVH had higher levels of circulating fibrinogen levels compared with those without LVH. We observed that circulating levels of fibrinogen, F1+2, vWF, and PAI-1 were not Hazard ratios (HRs) and 95% confidence interval (CI) of neurohumoral and hemostatic factor. Each model was adjusted by age, gender, smoking status, presence of diabetes mellitus, the use of antihypertensive drugs at follow-up time and high 24-hour BP. To assess the interaction between ECG-LVH and norepinephrine levels in relation to CVD events, model 2b included ECG-LVH, serum norepinephrine levels, and ECG-LVH × serum norepinephrine levels in the same models. Significance was defined as P < 0.05.
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; LVH, left ventricular hypertrophy.
significantly different between those with and without ECG-LVH. The reasons for the discrepant result remain uncertain, but racial differences in the circulating levels of hemostatic factors and their impacts on CVD events may exist. 28, 29 In the present study, the association between ECG-LVH and CVD events could not be explained by high 24-hour SBP, higher nocturnal SBP, and higher circulating levels of norepinephrine and hemostatic factors. Other potential mechanisms unmeasured in the present study include sleep apnea, 30 neurohumoral factors (e.g., circulating levels of angiotensin, aldosterone, and natriuretic peptide), 31, 32 and salt sensitivity. 33 These factors have been shown to share a common etiology of LVH and CVD events, and thus further investigations are required to determine whether the association between ECG-LVH and CVD events observed in the present study is independent of these uncontrolled factors. [30] [31] [32] [33] [34] [35] [36] There are several limitations in the present study. First, the number of CVD events was small, so we could not separate CVD events into stroke (or its subtypes) and myocardial infarction. Second, some patients received antihypertensive medication during follow-up, which could have led to underestimate true association between ECG-LVH and CVD events. Third, during the follow-up, 49 patients died; among them, 29 patients died from non-myocardial infarction or nonstroke, which may compete as outcomes. In other words, individuals may not experience myocardial infarction or stroke events for which they are destined if death occurs first. Fourth, we did not assess how many patients declined our offer to participate in the present study, suggesting the possibility of a selection bias. Lastly, our study patients were recruited from outpatients at clinics or hospitals in selected areas, so that our results may not be generalized to other race/ethnic populations or even other Japanese hypertensive elderly individuals.
Among older hypertensive patients, those with ECG-LVH had higher 24-hour and nocturnal SBP, and higher circulating norepinephrine levels compared to those without ECG-LVH. ECG-LVH was associated with a higher risk for CVD events, and the association was independent of higher 24-hour BP, nocturnal SBP, and circulating norepinephrine levels and other risk factors.
